远大医药(00512.HK)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望

智通财经
Jul 03
【远大医药(00512.HK)合作伙伴全球首创核药TLX591-Tx再传佳音 核药龙头带来前列腺癌治疗新希望】智通财经APP获悉,近日,远大医药(00512.HK)全球核药全球布局再度传来利好,公司在放射性核素偶联药物(RDC)领域的战略合作伙伴Telix Pharmaceuticals Limited (TLX.US)与美国FDA成功召开B类会议,FDA已确认全球创新RDC药物TLX591-Tx的国际多中心III期临床试验(ProstACT Global)第一部分安全性数据可以支持该产品在美国开展第二部分临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10